{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:27:42Z","timestamp":1786987662363,"version":"build-2736575974"},"reference-count":73,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T00:00:00Z","timestamp":1473811200000},"content-version":"vor","delay-in-days":349,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","derm.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.det.2015.05.007","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T23:28:26Z","timestamp":1438903706000},"page":"715-729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Auris O.","family":"Huen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2015.05.007_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5114\/pdia.2013.33375","article-title":"Oral retinoids and rexinoids in cutaneous T-cell lymphomas","volume":"30","author":"Soko\u0142owska-Wojdy\u0142o","year":"2013","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.det.2015.05.007_bib2","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1530\/EJE-13-0920","article-title":"Endocrine side-effects of anti-cancer drugs: the impact of retinoids on the thyroid axis","volume":"170","author":"Graeppi-Dulac","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.det.2015.05.007_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1529-8019.2006.00083.x","article-title":"Treatment of cutaneous T-cell lymphoma with retinoids","volume":"19","author":"Zhang","year":"2006","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2015.05.007_bib4","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2002-01-0300","article-title":"Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox","volume":"100","author":"Gorgun","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.007_bib5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0889-8588(03)00107-2","article-title":"Topical and systemic retinoid therapy for cutaneous T-cell lymphoma","volume":"17","author":"Kempf","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.det.2015.05.007_bib6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-pathol-011110-130303","article-title":"Retinoids, retinoic acid receptors, and cancer","volume":"6","author":"Tang","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.det.2015.05.007_bib7","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1200\/JCO.1994.12.6.1185","article-title":"Use of retinoic acids in the treatment of peripheral T-cell lymphoma: a pilot study","volume":"12","author":"Cheng","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.007_bib8","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.det.2015.05.007_bib9","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.007_bib10","unstructured":"National Comprehensive Cancer Network Guidelines. Non-Hodkin\u2019s Lymphoma. Version 5.2014. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/nhl.pdf. Accessed February, 2015."},{"key":"10.1016\/j.det.2015.05.007_bib11","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(83)92136-0","article-title":"Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid","volume":"1","author":"Kessler","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.det.2015.05.007_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(83)90717-1","article-title":"Isotretinoin in cutaneous t-cell lymphoma","volume":"322","author":"Warrell","year":"1983","journal-title":"Lancet"},{"issue":"Supplement 3","key":"10.1016\/j.det.2015.05.007_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/j.seminoncol.2005.12.016","article-title":"Therapeutic advances in cutaneous T-Cell lymphoma (CTCL): from retinoids to rexinoids","volume":"33","author":"Stadler","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.det.2015.05.007_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4161\/derm.1.3.9364","article-title":"The use of isotretinoin in acne","volume":"1","author":"Layton","year":"2009","journal-title":"Dermatoendocrinol"},{"key":"10.1016\/j.det.2015.05.007_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.smim.2008.07.002","article-title":"Regulation of CD8(+) T cell functions by RARgamma","volume":"21","author":"Gordy","year":"2009","journal-title":"Semin Immunol"},{"key":"10.1016\/j.det.2015.05.007_bib16","first-page":"1129","article-title":"Synthetic retinoids in dermatology","volume":"132","author":"Heller","year":"1985","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.det.2015.05.007_bib17","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0190-9622(82)80060-1","article-title":"Retinoids and inhibition of ornithine decarboxylase activity","volume":"6","author":"Boutwell","year":"1982","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"Supplement 1","key":"10.1016\/j.det.2015.05.007_bib18","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.3816\/CLM.2000.s.008","article-title":"Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL)","volume":"1","author":"Burg","year":"2000","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.det.2015.05.007_bib19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2133.2008.08931.x","article-title":"Bexarotene activates the p53\/p73 pathway in human cutaneous T-cell lymphoma","volume":"160","author":"Nieto-Rementer\u00eda","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib20","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.bjc.6602995","article-title":"A\u00a0selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours","volume":"94","author":"Yen","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.det.2015.05.007_bib21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/1523-1747.ep12413014","article-title":"Retinoic acid upregulates human Langerhans cell antigen presentation and surface expression of HLA-DR and CD11c, a beta 2 integrin critically involved in T-cell activation","volume":"103","author":"Meunier","year":"1994","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1749-6632.1996.tb52680.x","article-title":"The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma","volume":"795","author":"Rook","year":"1996","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.det.2015.05.007_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/cimm.1993.1003","article-title":"Upregulation by retinoic acid of interleukin-2-receptor mRNA in human T lymphocytes","volume":"146","author":"Sidell","year":"1993","journal-title":"Cell Immunol"},{"key":"10.1016\/j.det.2015.05.007_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archderm.1987.01660260071016","article-title":"Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides)","volume":"123","author":"Kessler","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2133.2005.06360.x","article-title":"Follicular cutaneous T-cell lymphoma: beneficial effect of isotretinoin for persisting cysts and comedones","volume":"152","author":"Leverkus","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib26","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0190-9622(99)70359-2","article-title":"Acitretin in psoriasis: an overview of adverse effects","volume":"41","author":"Katz","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2133.1983.tb03991.x","article-title":"Treatment of cutaneous lymphoma with etretinate","volume":"109","author":"Claudy","year":"1983","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2340\/0001555567232236","article-title":"Oral retinoids in mycosis fungoides and S\u00e9zary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group","volume":"67","author":"Molin","year":"1987","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2015.05.007_bib29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jaad.2012.07.013","article-title":"Acitretin for the treatment of cutaneous T-cell lymphoma","volume":"68","author":"Cheeley","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/107999099314117","article-title":"Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells","volume":"19","author":"Fox","year":"1999","journal-title":"J\u00a0Interferon Cytokine Res"},{"key":"10.1016\/j.det.2015.05.007_bib31","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI200524826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.det.2015.05.007_bib32","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib33","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.007_bib34","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","article-title":"Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome","volume":"160","author":"Abbott","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib35","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1365-2133.2008.08487.x","article-title":"Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial","volume":"158","author":"Ruzicka","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib36","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/00128071-200203070-00002","article-title":"Recent advances in the treatment of AIDS-related Kaposi\u2019s sarcoma","volume":"3","author":"Cattelan","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib37","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/j.jaad.2012.05.011","article-title":"Treatment of 2 patients with mycosis fungoides with alitretinoin","volume":"67","author":"Coors","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2015.05.007_bib38","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/jdv.12684","article-title":"Treatment of cutaneous T-cell lymphoma with oral alitretinoin","volume":"29","author":"Kapser","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2015.05.007_bib39","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.007_bib40","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.007_bib41","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ctrv.2014.06.005","article-title":"Systematic review of combination therapies for mycosis fungoides","volume":"40","author":"Humme","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.det.2015.05.007_bib42","first-page":"536","article-title":"Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group","volume":"69","author":"Thomsen","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2015.05.007_bib43","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.007_bib44","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaad.2003.05.010","article-title":"Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series","volume":"51","author":"Singh","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00128071-200809030-00005","article-title":"Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides","volume":"9","author":"Papadavid","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib46","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2133.2012.11156.x","article-title":"Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056)","volume":"167","author":"Whittaker","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/09546630903103980","article-title":"Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB","volume":"21","author":"D\u2019Acunto","year":"2010","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.det.2015.05.007_bib48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-0781.2007.00315.x","article-title":"Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides","volume":"23","author":"Lokitz","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.det.2015.05.007_bib49","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0190-9622(91)70036-2","article-title":"Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids","volume":"24","author":"Knobler","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib51","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0190-9622(96)90282-0","article-title":"Combined modality therapy for cutaneous T-cell lymphoma","volume":"34","author":"Duvic","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib52","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncr.20009","article-title":"Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.det.2015.05.007_bib53","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.det.2015.05.007_bib54","first-page":"29","article-title":"Optimal combination with PUVA: rationale and clinical trial update","volume":"21","author":"Stadler","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.det.2015.05.007_bib55","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1365-2133.2007.07901.x","article-title":"Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and S\u00e9zary syndrome","volume":"156","author":"Tsirigotis","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib56","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archderm.141.9.1176","article-title":"The addition of interferon gamma to oral bexarotene therapy with photopheresis for S\u00e9zary syndrome","volume":"141","author":"McGinnis","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib57","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","article-title":"A\u00a0phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"106","author":"Foss","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.007_bib58","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3109\/10428194.2012.656625","article-title":"Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in\u00a0vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor\/retinoid X receptor activation by histone deacetylase inhibition","volume":"53","author":"Dummer","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.det.2015.05.007_bib59","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/09546630802562427","article-title":"Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma","volume":"20","author":"Kannangara","year":"2009","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.det.2015.05.007_bib60","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clml.2014.01.010","article-title":"Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed\/refractory mycosis fungoides","volume":"14","author":"Talpur","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.det.2015.05.007_bib61","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1038\/bjc.2013.616","article-title":"Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma","volume":"109","author":"Illidge","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.det.2015.05.007_bib62","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/archderm.141.3.315","article-title":"Biological effects of bexarotene in cutaneous T-cell lymphoma","volume":"141","author":"Budgin","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib63","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2008-03-141424","article-title":"Clinical and in\u00a0vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor","volume":"112","author":"Lin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.007_bib64","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1067\/mjd.2001.113718","article-title":"Regulation of lipid and lipoprotein metabolism by retinoids","volume":"45","author":"Staels","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib65","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/dth.12085","article-title":"Oral retinoids and plasma lipids","volume":"26","author":"Lilley","year":"2013","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2015.05.007_bib66","doi-asserted-by":"crossref","first-page":"582","DOI":"10.7326\/0003-4819-136-8-200204160-00007","article-title":"High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study","volume":"136","author":"Rodondi","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.det.2015.05.007_bib67","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJM199904083401404","article-title":"Central hypothyroidism associated with retinoid X receptor-selective ligands","volume":"340","author":"Sherman","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2015.05.007_bib68","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3816\/CLM.2003.n.006","article-title":"Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma","volume":"3","author":"Sherman","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.det.2015.05.007_bib69","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/1523-1747.ep12472293","article-title":"Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol","volume":"100","author":"Larsen","year":"1993","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib70","unstructured":"Targretin [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals NA LLC; 2013."},{"key":"10.1016\/j.det.2015.05.007_bib71","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjd.12042","article-title":"UK consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma","volume":"168","author":"Scarisbrick","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.007_bib72","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2340\/0001555564563566","article-title":"13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group","volume":"64","author":"Thomsen","year":"1984","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2015.05.007_bib73","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinte.1987.00370030133026","article-title":"The effect of isotretinoin in six patients with cutaneous T-cell lymphoma","volume":"147","author":"Neely","year":"1987","journal-title":"Arch Intern Med"}],"updated-by":[{"DOI":"10.1016\/j.det.2018.02.018","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000}}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T07:58:41Z","timestamp":1718006321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863515000522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0733863515000522"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2015.05.007","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2015.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}